Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MCET Multicell Patent US 7566567 B2 Immortalized Human Hepatocyte Cell Lines: GOVERNMENT GRANTS
This invention was made in part with United States government support under grant number 70-NANB7H3070 awarded by Advanced Technology Program of the United States Department of Commerce. The U.S. government has certain rights in this invention.
All info about Patent US 7566567 B2: http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7566567
Goes UP todamoooon shine 0.00++!
$IDGC $$$$ ALERTS BOOOOOOOM $$$$$
Yeah thats nice hit over 0.00+ $$$$$$$ GO $IDGC!
$MCET Granted Patent Drug: Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA).
https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
INTRODUCTION
Primary cultures of human hepatocytes are widely used to evaluate the cytochrome P450 (CYP) enzyme-inducing potential and/or toxicity of drug candidates. However, the availability of human hepatocytes for this purpose is limited and erratic, and there are large inter-individual differences in the magnitude of induction (due to differences in both
"control" and "induced" CYP activities). Immortalized human hepatocytes, Fa2N-4, developed by Multicell Technologies, (Warwick, RI) have the potential to overcome these limitations. The cells, immortalized through transformation of human hepatocytes with SV40 T antigen, display in vitro cell morphology that closely resembles primary human hepatocytes (Figure 1). The Fa2N-4 cells retain many of the characteristics of primary hepatocytes, including the inducibility of multiple CYP mRNAs and enzyme activities (Mills et al., 2002; Morris et al., 2003; Czerwinski et al., 2003). In this study, we further characterized the ability of these cells to respond to enzymeinducing xenobiotics. Additionally, we examined the toxicity profile of multiple enzyme inducers in primary hepatocytes and Fa2N-4 cells.
MATERIALS AND METHODS
The Fa2N-4 cells were propagated in MFE media (Multicell Technologies) on plasticware coated with Vitrogen (Cohesion Technologies, Palo Alto, CA) and maintained at 37°C, 5% CO2, 95% humidity. Immortalized hepatocytes were grown to confluency in 24 or 96-well plates and treated with enzyme inducers for up to 6 consecutive days with daily changes of medium. All enzyme inducers were dissolved in DMSO (final concentration of solvent 0.1%, v/v). Primary human hepatocytes were isolated and cultured as described (LeCluyse et al., 2000, Madan et al., 2003). Enzymatic activities were determined by incubating the cells with CYPspecific substrates. Metabolite formation was measured by LC-MS as summarized in Table 1.
The Use of Immortalized Hepatocytes in Induction Studies https://www.xenotech.com/access-adme-research-resources/resources/the-use-of-immortalized-hepatocytes-in-induction-studies/
https://www.xenotech.com/wp-content/uploads/2004/08/The-Use-of-Immortalized-Hepatocytes-in-Induction-Studies.pdf
Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!
Multicell Technologies Immortalized Hepatocytes
InventorJin LiuRonald A. FarisCurrent Assignee Multicell Technologies Inc
US 7566567 B2
Doc Type: Granted Patent
ID: lens.org/167-627-709-236-287
Jul 28, 2009
Application US10/574,163 events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2007-01-04
Publication of US20070004039A1
2009-07-28
Publication of US7566567B2
2009-07-28
Application granted
Status Active
2025-01-13
Adjusted expiration
https://patents.google.com/patent/US7566567B2/un
EP 1704227 B1
Doc Type: Granted Patent
ID: lens.org/097-040-197-694-101
Jan 27, 2010
EP1704227B1 European Patent Office
Application EP04794437A events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2006-09-27
Publication of EP1704227A1
2007-01-17
Publication of EP1704227A4
2010-01-27
Application granted
2010-01-27
Publication of EP1704227B1
Status Active
2024-10-07
Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en
DE 602004025380 D1
Doc Type: Granted Patent
ID: lens.org/082-791-344-403-259
Mar 18, 2010
Application DE602004025380T events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2010-03-18
Publication of DE602004025380D1
Status Active
2024-10-08
Anticipated expiration
https://patents.google.com/patent/DE602004025380/D1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-287
$MCET Granted Patent Drug: Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA).
https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
INTRODUCTION
Primary cultures of human hepatocytes are widely used to evaluate the cytochrome P450 (CYP) enzyme-inducing potential and/or toxicity of drug candidates. However, the availability of human hepatocytes for this purpose is limited and erratic, and there are large inter-individual differences in the magnitude of induction (due to differences in both
"control" and "induced" CYP activities). Immortalized human hepatocytes, Fa2N-4, developed by Multicell Technologies, (Warwick, RI) have the potential to overcome these limitations. The cells, immortalized through transformation of human hepatocytes with SV40 T antigen, display in vitro cell morphology that closely resembles primary human hepatocytes (Figure 1). The Fa2N-4 cells retain many of the characteristics of primary hepatocytes, including the inducibility of multiple CYP mRNAs and enzyme activities (Mills et al., 2002; Morris et al., 2003; Czerwinski et al., 2003). In this study, we further characterized the ability of these cells to respond to enzymeinducing xenobiotics. Additionally, we examined the toxicity profile of multiple enzyme inducers in primary hepatocytes and Fa2N-4 cells.
MATERIALS AND METHODS
The Fa2N-4 cells were propagated in MFE media (Multicell Technologies) on plasticware coated with Vitrogen (Cohesion Technologies, Palo Alto, CA) and maintained at 37°C, 5% CO2, 95% humidity. Immortalized hepatocytes were grown to confluency in 24 or 96-well plates and treated with enzyme inducers for up to 6 consecutive days with daily changes of medium. All enzyme inducers were dissolved in DMSO (final concentration of solvent 0.1%, v/v). Primary human hepatocytes were isolated and cultured as described (LeCluyse et al., 2000, Madan et al., 2003). Enzymatic activities were determined by incubating the cells with CYPspecific substrates. Metabolite formation was measured by LC-MS as summarized in Table 1.
The Use of Immortalized Hepatocytes in Induction Studies https://www.xenotech.com/access-adme-research-resources/resources/the-use-of-immortalized-hepatocytes-in-induction-studies/
https://www.xenotech.com/wp-content/uploads/2004/08/The-Use-of-Immortalized-Hepatocytes-in-Induction-Studies.pdf
Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!
Multicell Technologies Immortalized Hepatocytes
InventorJin LiuRonald A. FarisCurrent Assignee Multicell Technologies Inc
US 7566567 B2
Doc Type: Granted Patent
ID: lens.org/167-627-709-236-287
Jul 28, 2009
Application US10/574,163 events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2007-01-04
Publication of US20070004039A1
2009-07-28
Publication of US7566567B2
2009-07-28
Application granted
Status Active
2025-01-13
Adjusted expiration
https://patents.google.com/patent/US7566567B2/un
EP 1704227 B1
Doc Type: Granted Patent
ID: lens.org/097-040-197-694-101
Jan 27, 2010
EP1704227B1 European Patent Office
Application EP04794437A events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2006-09-27
Publication of EP1704227A1
2007-01-17
Publication of EP1704227A4
2010-01-27
Application granted
2010-01-27
Publication of EP1704227B1
Status Active
2024-10-07
Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en
DE 602004025380 D1
Doc Type: Granted Patent
ID: lens.org/082-791-344-403-259
Mar 18, 2010
Application DE602004025380T events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2010-03-18
Publication of DE602004025380D1
Status Active
2024-10-08
Anticipated expiration
https://patents.google.com/patent/DE602004025380/D1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-287
$IDGC Huge RUN! More BIG BUYS! Amazing $$$$$$$$
$IDGC Huge hit up over 0.00+ $$$$$$
$IDGC Huge hit up over 0.00+ $$$$$$
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Huge RUN! More BIG BUYS! Amazing $$$$$$$$
$IDGC GOES UP! Great start! Big BUYS and up to 9s $$$$$$$$
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
$MCET GOVERNMENT GRANTS: Product Details Fa2N-4 Line Price and LICENSE AGREEMENT: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161097767
$MCET GOVERNMENT GRANTS: Product Details Fa2N-4 Line Price and LICENSE AGREEMENT: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161097767
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
The Use of Immortalized Hepatocytes in Induction Studies
https://www.xenotech.com/access-adme-research-resources/resources/the-use-of-immortalized-hepatocytes-in-induction-studies/
Abstract
Primary cultures of human hepatocytes are widely used to evaluate the cytochrome P450 (CYP) enzyme-inducing potential and/or toxicity of drug candidates. However, the availability of Human hepatocytes for this purpose is limited and erratic, and there are large inter-individual differences in the magnitude of induction (due to differences in both “control” and “induced” CYP activities). Immortalized Human hepatocytes, Fa2N-4, developed by Multicell Technologies, (Warwick, RI) have the potential to overcome these limitations. The cells, immortalized through transformation of Human hepatocytes with SV40 T antigen, display in vitro cell morphology that closely resembles primary Human hepatocytes (Figure 1). The Fa2N-4 cells retain many of the characteristics of primary hepatocytes, including the inducibility of multiple CYP mRNAs and enzyme activities (Mills et al., 2002; Morris et al., 2003; Czerwinski et al., 2003).
In this study, we further characterized the ability of these cells to respond to enzyme-inducing xenobiotics. Additionally, we examined the toxicity profile of multiple enzyme inducers in primary hepatocytes and Fa2N-4 cells.
>>>>>> https://www.xenotech.com/wp-content/uploads/2004/08/The-Use-of-Immortalized-Hepatocytes-in-Induction-Studies.pdf
Answer to that! MultiCell Takes Control of Cell Marketing Program
https://www.businesswire.com/news/home/20060206005451/en/MultiCell-Takes-Control-of-Cell-Marketing-Program
It was recently deleted! Why???
Yeah thats it!
Nice close today!
$IDGC .0007 Volume: 372,722,586 HUGE BIG BUYS ACTION $$$$$$$$
$IDGC .0007 Volume: 372,722,586 HUGE BIG BUYS ACTION $$$$$$$$
SRO List - Detail
DUNS NUMBER: 173651688
BUSINESS NAME: Multicell Technologies, Inc.
COUNTRY NAME: USA
TICKER SYMBOL: MCET
EXCHANGE NAME: OTHER OTC Market
Page Last Updated: 01/22/2021
https://www.accessdata.fda.gov/scripts/SDA/sdDetailNavigation.cfm?sd=srolist&id=B9813678BF264C61E0530D98C30A0B6F&rownum=1182
$IDGC BIG BUYS! BOOOOM UP to 8s! 9s .... $$$$$$$$$
$IDGC hit 8s!
$IDGC hit 8s!
$MCET Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
$MCET Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
This is how the project started: License Agreement
License Agreement for EXTEN INDUSTRIES INC, XenoTech, LLC, , MultiCell Technologies, Inc., https://www.realdealdocs.com/viewdocument.aspx?DocumentID=14890
MultiCell signs licensing deal worth $19M
Aug 18, 2003, 12:00am EDT https://www.bizjournals.com/boston/blog/mass-high-tech/2003/08/multicell-signs-licensing-deal-worth-19m.html
MultiCell Cell Lines Introduced Worldwide as New Findings Expand Potential Use of MCT Technology
October 30, 2003 02:08 PM https://www.businesswire.com/news/home/20031030005610/en/MultiCell-Cell-Lines-Introduced-Worldwide-as-New-Findings-Expand-Potential-Use-of-MCT-Technology
MultiCell Technologies and XenoTech LLC Jointly Announce Shrink Wrap Vial Sales Launch for Immortalized Hepatocytes
June 15, 2005 09:15 AM https://www.businesswire.com/news/home/20050615005537/en/MultiCell-Technologies-XenoTech-LLC-Jointly-Announce-Shrink
Info about Multicell Fa2N-4 License partner SEKISUI XENOTECH: https://www.xenotech.com/about/history/
$MCET Volume goes up! More slaps approved! Its going up!
$MCET Volume goes up! More slaps approved! Its going up!
$MCET GOES UP! AMAZING $$$$$$$$$$
$MCET AND: Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET AND: Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402